Payment overview · 2025
General Payments
$1,071.01
64 reported records · 19 companies
Healthcare provider profile · identity verified
James A Miller, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MONROE, MI · NPI 1841297256
Verified facts
What the public records show
CMS Open Payments records show James A Miller, D.O. received $1,071.01 in general payments during 2025 across 64 reported records.
ABBVIE INC. accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $208.94 | 19.5% | 13 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $168.94 | 15.8% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $144.78 | 13.5% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.22 | 5.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.44 | 5.3% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $53.32 | 5.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $51.47 | 4.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.12 | 4.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $42.29 | 4.0% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $38.20 | 3.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.84 | 3.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $30.89 | 2.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.15 | 2.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.75 | 2.0% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.56 | 2.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.64 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.33 | 1.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.29 | 1.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.84 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,071.01 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $144.78 | 11 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $112.42 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $96.35 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $78.71 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $56.52 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $53.32 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $51.47 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $42.29 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $38.20 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.93 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.86 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.84 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.26 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $30.89 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $30.34 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $3.54 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $3.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 238 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
62 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
238 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 809 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 673 | 180 |
| Lisinopril | Lisinopril | 529 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 512 | 123 |
| Omeprazole | Omeprazole | 381 | 104 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 367 | 45 |
| Metformin Hcl | Metformin Hcl | 358 | 90 |
| Gabapentin | Gabapentin | 308 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 75 |
| Simvastatin | Simvastatin | 259 | 62 |
| Meloxicam | Meloxicam | 248 | 78 |
| Lorazepam | Lorazepam | 247 | 56 |
| Alprazolam | Alprazolam | 244 | 36 |
| Eliquis | Apixaban | 238 | 35 |
| Furosemide | Furosemide | 232 | 75 |
| Potassium Chloride | Potassium Chloride | 216 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 213 | 65 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 197 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 48 |
| Clonazepam | Clonazepam | 176 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 48 |
| Ibuprofen | Ibuprofen | 164 | 62 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 160 | 45 |
| Pioglitazone Hcl | Pioglitazone Hcl | 159 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 48 |
| Tramadol Hcl | Tramadol Hcl | 149 | 34 |
| Losartan Potassium | Losartan Potassium | 137 | 40 |
| Sertraline Hcl | Sertraline Hcl | 136 | 21 |
| Donepezil Hcl | Donepezil Hcl | 134 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 132 | 28 |
| Carvedilol | Carvedilol | 130 | 32 |
| Atenolol | Atenolol | 117 | 32 |
| Diazepam | Diazepam | 117 | 26 |
| Cephalexin | Cephalexin | 116 | 83 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 116 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 24 |
| Montelukast Sodium | Montelukast Sodium | 103 | 31 |
| Prednisone | Prednisone | 103 | 40 |
| Ropinirole Hcl | Ropinirole Hcl | 103 | 26 |
| Trazodone Hcl | Trazodone Hcl | 99 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 98 | 73 |
| Jardiance | Empagliflozin | 95 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 18 |
| Allopurinol | Allopurinol | 85 | 24 |
| Buspirone Hcl | Buspirone Hcl | 84 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 17 |
| Methylprednisolone | Methylprednisolone | 83 | 65 |
| Pregabalin | Pregabalin | 83 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 21 |
| Azithromycin | Azithromycin | 76 | 50 |
| Clonidine Hcl | Clonidine Hcl | 74 | 23 |
| Glipizide | Glipizide | 74 | 22 |
| Metformin Hcl Er | Metformin Hcl | 70 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 63 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 19 |
| Meclizine Hcl | Meclizine Hcl | 57 | 22 |
| Permethrin | Permethrin | 57 | 27 |
| Sumatriptan Succinate | Sumatriptan Succinate | 57 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 16 |
| Trulicity | Dulaglutide | 56 | 13 |
| Temazepam | Temazepam | 55 | 13 |
| Nifedipine Er | Nifedipine | 53 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 40 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 50 | 14 |
| Acyclovir | Acyclovir | 49 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 20 |
| Memantine Hcl | Memantine Hcl | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | 13 |
| Celecoxib | Celecoxib | 45 | 13 |
| Tradjenta | Linagliptin | 45 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Baclofen | Baclofen | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | suppressed |
| Glipizide Er | Glipizide | 40 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 40 | suppressed |
| Finasteride | Finasteride | 39 | 14 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Bumetanide | Bumetanide | 36 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 26 |
| Glyburide Micronized | Glyburide,micronized | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 19 |
| Fluconazole | Fluconazole | 32 | 11 |
| Colchicine | Colchicine | 31 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | 11 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 27 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Ozempic | Semaglutide | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | 11 |
| Glyburide | Glyburide | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Spironolactone | Spironolactone | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | 14 |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lyumjev | Insulin Lispro-Aabc | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | 13 |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Trileptal | Oxcarbazepine | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Keppra | Levetiracetam | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,071.01 · 64 records | ABBVIE INC. | Auvelity, BOTOX, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, ELIQUIS, ENTRESTO, FANAPT, GEMTESA, HETLIOZ, JOURNAVX, KISUNLA, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, XYOSTED, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error